Leflunomide regulates c-Myc expression in myeloma cells through PIM targeting
R Buettner, C Morales, E Caserta, E Troadec… - Blood …, 2019 - ashpublications.org
Blood Advances, 2019•ashpublications.org
Leflunomide regulates c-Myc expression in myeloma cells through PIM targeting | Blood
Advances | American Society of Hematology Skip to Main Content Advertisement intended for
health care professionals Umbrella Alt Text Umbrella Alt Text Close ASH Clinical News ASH
News Daily ASH-SAP Blood Journals Blood Blood Advances Blood Global Hematology Blood
Immunology & Cellular Therapy Blood Neoplasia Blood Red Cells & Iron Blood Vessels,
Thrombosis & Hemostasis Hematology The Hematologist International Blood Chinese Edition …
Advances | American Society of Hematology Skip to Main Content Advertisement intended for
health care professionals Umbrella Alt Text Umbrella Alt Text Close ASH Clinical News ASH
News Daily ASH-SAP Blood Journals Blood Blood Advances Blood Global Hematology Blood
Immunology & Cellular Therapy Blood Neoplasia Blood Red Cells & Iron Blood Vessels,
Thrombosis & Hemostasis Hematology The Hematologist International Blood Chinese Edition …
Key Points
- Teriflunomide, the active metabolite of leflunomide, downregulates c-Myc expression through inhibition of PIM kinases.
- Leflunomide together with lenalidomide significantly extended survival in an in vivo MM model.
ashpublications.org